Harrow (FRA:3IP) Total Premiums Earned

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3IP Harrow Inc FRA:3IP
76 GF Score
Price €33.00
GF Value €35.28
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Harrow Total Premiums Earned?

Total Premiums Earned only applies to insurance companies.

FRA:3IP
76GF Score
Harrow Inc FRA:3IP
Total Premiums Earned is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Harrow (FRA:3IP) Overvalued in 2026?

Based on GuruFocus' analysis, Harrow stock appears to be undervalued. The current stock price of €33.00 is trading 6.5% below its estimated GF Value™ of €35.28. GuruFocus considers Harrow to be Fairly Valued.

Key valuation signals for FRA:3IP:

  • Total Premiums Earned:
  • GF Value™: €35.28 vs. price of €33.00 (6.5% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the FRA:3IP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harrow Business Description

Other Exchanges HROW:USA
Address 1A Burton Hills Boulevard, Suite 200, Nashville, TN, USA, 37215
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
76GF Score

Get the complete analysis for FRA:3IP

Total Premiums Earned is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.00
Price
€35.28
GF Value